Fig. 2: Objective response to letrozole/abemaciclib/metformin.
From: Letrozole, abemaciclib and metformin in endometrial cancer: a non-randomized phase 2 trial
A Best change in target lesions from baseline in all patients evaluable for RECIST 1.1 response. a denotes patients still on protocol therapy as of the data cut-off date. B Spider plot for all evaluable patients.
